Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03710902

Empowerment and Mobile Technology in the Control of Cardiovascular Risk Factors in Patients With Ischemic Stroke

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
405 (estimated)
Sponsor
Jukka Putaala · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

The CARDIOSTROKE is a randomized trial comparing mobile-device assisted control of hypertension together with screening of occult atrial fibrillation to standard care in patients with recent ischemic stroke or transient ischemic attack.

Detailed description

Atrial fibrillation (AF) and hypertension are among the main treatable risk factors for ischemic stroke and transient ischemic attack (TIA). Detecting paroxysmal atrial fibrillation in stroke patients is challenging, but highly relevant since anticoagulation can effectively reduce the risk of recurrent strokes. Furthermore, hypertension remains poorly controlled even after stroke despite multiple available treatment options. In the CARDIOSTROKE trial, the investigators aim to randomize 405 patients with recent ischemic stroke or TIA into (1) standard diagnostic work-up, follow-up and treatment (control group) and (2) 3-week ECG monitoring to detect occult AF and self-monitoring of blood pressure with mobile-device-assisted self-titration of antihypertensive medication (intervention group). Randomization will occur 2:1 into control and intervention groups. The co-primary outcomes include (1) incidence of new-onset AF and (2) difference in the mean blood pressure at 12-months.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTECG monitoring for 3 weeksA 3-week continuous ECG monitoring to detect occult AF.
OTHERSelf-monitoring of BP and self-titration of antihypertensive medicationOne-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.

Timeline

Start date
2018-10-17
Primary completion
2026-09-01
Completion
2028-09-01
First posted
2018-10-18
Last updated
2025-03-20

Locations

4 sites across 1 country: Finland

Source: ClinicalTrials.gov record NCT03710902. Inclusion in this directory is not an endorsement.